SANDOZ LEVODOPA-CARBIDOPA-ENTACAPONE 125 MG
LEVODOPA : 125 MG CARBIDOPA : 31.25 MG ENTACAPONE : 200 MG · DIN 02498871 · SANDOZ CANADA INCORPORATED
Health Canada status: APPROVED
What is SANDOZ LEVODOPA-CARBIDOPA-ENTACAPONE?
SANDOZ LEVODOPA-CARBIDOPA-ENTACAPONE 125 MG contains LEVODOPA : 125 MG CARBIDOPA : 31.25 MG ENTACAPONE : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02498871, held by SANDOZ CANADA INCORPORATED, supplied as TABLET for ORAL administration. Health Canada currently lists it as approved, status dated 15-May-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02498871 |
|---|---|
| Brand name | SANDOZ LEVODOPA-CARBIDOPA-ENTACAPONE |
| Generic / active ingredient | LEVODOPA : 125 MG CARBIDOPA : 31.25 MG ENTACAPONE : 200 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 125 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N04BA03 LEVODOPA,DECARBOXYLASE INHIBITOR, AND COMT INHIBITOR |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 15-May-2020 |
What can be used instead?
Other Canadian products sharing ATC code N04BA03 LEVODOPA,DECARBOXYLASE INHIBITOR, AND COMT INHIBITOR. 5 of 12 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| STALEVO | 200 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02305933 |
| STALEVO | 200 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02305941 |
| STALEVO | 200 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02337835 |
| STALEVO | 37.5 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02305968 |
| STALEVO | 75 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02337827 |
| LEVODOPA, CARBIDOPA AND ENTACAPONE TABLETS | 37.5 MG | TABLET | STRIDES PHARMA CANADA INC | APPROVED | DIN 02517884 |
| LEVODOPA, CARBIDOPA AND ENTACAPONE TABLETS | 50 MG | TABLET | STRIDES PHARMA CANADA INC | APPROVED | DIN 02517876 |
| SANDOZ LEVODOPA-CARBIDOPA-ENTACAPONE | 150 MG | TABLET | SANDOZ CANADA INCORPORATED | APPROVED | DIN 02498901 |
| SANDOZ LEVODOPA-CARBIDOPA-ENTACAPONE | 200 MG | TABLET | SANDOZ CANADA INCORPORATED | APPROVED | DIN 02498898 |
| SANDOZ LEVODOPA-CARBIDOPA-ENTACAPONE | 25 MG | TABLET | SANDOZ CANADA INCORPORATED | APPROVED | DIN 02498863 |
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ask about availability of SANDOZ LEVODOPA-CARBIDOPA-ENTACAPONE
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.